Volume 9 Supplement 9
Implementation of a quality by design approach into cell line and process development for recombinant protein production
© Noack et al. 2015
Published: 14 December 2015
Cellca is a recognized leader in cell line and upstream process development for large-scale protein production of biopharmaceuticals (e.g. antibodies) in mammalian cells and offers a unique platform technology which is characterized by high efficiency regarding productivity, scalability, and protein quality. As the market for therapeutic proteins is steadily growing, the need to optimize methods for the generation of mammalian cell lines is steadily increasing. In this context, important aspects are to express recombinant proteins not only at high levels and in an efficient cost-effective manner, but also with the desired protein quality attributes such as the glycoprofile. Cellca's unique platform technology enables the expression of antibody products with different protein quality attributes using only a single host cell line. We identified three steps to select, optimize and confirm scalability of a high-producing cell line expressing proteins with the desired quality profile. Thus, with this study we aim to contribute to a better understanding of how quality in terms of expressing proteins with pre-defined glycoprofiles can be built into a cell line and process development process.
Materials and methods
A recombinant CHO DG44 cell line expressing an IgG1 antibody was developed using Cellca´s proprietary platform technology. For this purpose, different cell clones were generated and subsequently evaluated in a platform fed-batch process at shake flask scale for their producer cell line potential. Product quality analysis was implemented into the development process early on and allowed selection of the clone with the most desirable product quality profile. For media and process variation studies, cells were cultured in fed-batch mode in both shake flask and bioreactor scale using Cellca's platform process and proprietary cell culture media. Cell densities and culture viabilities were obtained using a CASY cell counter. Antibody concentrations were determined by Protein A HPLC. Bioreactor experiments in 200 L and 1000 L scale were performed at Rentschler Biotechnologie GmbH (Laupheim, Germany). Analytical data of product quality was provided by Protagen Protein Services GmbH (Dortmund, Germany). The Galactosylation index was calculated according to Kunkel et al .
It becomes increasingly important to express recombinant proteins not only at high levels and in an efficient cost-effective manner, but also with the desired protein quality attributes, e.g. the glycoprofile. In this study, we presented an approach of how quality in terms of expressing proteins with pre-defined glycoprofiles can be built into a cell line and process development process.
A main building block and starting point for cell line development is Cellca's CHO DG44 host cell line, which can be flexibly used to produce antibodies that cover a broad range of various quality attributes. Thus, there is no need to screen several host cell lines for expression of the correct target antibody characteristics, as one cell line and the technology platform associated with it is sufficient to express different antibody products each with their individual protein quality attributes. In the present study, we developed a recombinant cell line expressing a monoclonal human IgG1 antibody. Implementing a quality by design approach for pool and clone selection allowed to pre-select cell pools based on their glycan profile before single cell cloning. Subsequently, high-producing cell clones that expressed the target antibody with a desirable protein quality profile were identified in a standard fed-batch process and used for further studies. We showed that the galactosylation profile can be influenced, both towards higher and lower galactosylation levels, by media and process variation. As depicted in Figure 1B, effective clone selection as well as media and process optimization enabled to match the N-glycosylation pattern of the expressed IgG1 antibody to a reference protein. The optimized production process was scalable from 25 mL shake flask up to 1000 L bioreactor levels regarding growth, productivity and glycosylation. Implementing the quality by design approach into cell line and process development can thus enable to successfully target a desired protein quality profile.
This project was supported by the German Federal Ministry for Economics and Technology (BMWi) through a ZIM (Central innovation program for medium-sized companies) project grant. We would like to thank Martin Blüggel of Protagen Protein Services GmbH, Dortmund, for the performance of product quality analytics. Furthermore, the author would like to thank Rentschler Biotechnologie GmbH, Laupheim, in particular Sven Reiser for the performance of the bioreactor studies in 200 L and 1000 L scale.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.